Magma Ascent along a Major Terrane Boundary: Crustal Contamination and Magma Mixing at the Drumadoon Intrusive Complex, Isle of Arran, Scotland

The composite intrusions of Drumadoon and An Cumhann crop out on the SE coast of the Isle of Arran, Scotland and form part of the larger British and Irish Palaeogene Igneous Province, a subset of the North Atlantic Igneous Province. The intrusions (shallow-level dykes and sills) comprise a central quartz-feldspar-phyric rhyolite flanked by xenocryst-bearing basaltic andesite, with an intermediate zone of dark quartz-feldspar-phyric dacite. New geochemical data provide information on the evolution of the component magmas and their relationships with each other, as well as their interaction with the crust through which they travelled. During shallow-crustal emplacement, the end-member magmas mixed. Isotopic evidence shows that both magmas were contaminated by the crust prior to mixing; the basaltic andesite magma preserves some evidence of contamination within the lower crust, whereas the rhyolite mainly records upper-crustal contamination. The Highland Boundary Fault divides Arran into two distinct terranes, the Neoproterozoic to Early Palaeozoic Grampian Terrane to the north and the Palaeozoic Midland Valley Terrane to the south. The Drumadoon Complex lies within the Midland Valley Terrane but its isotopic signatures indicate almost exclusive involvement of Grampian Terrane crust. Therefore, although the magmas originated at depth on the northern side of the Highland Boundary Fault, they have crossed this boundary during their evolution, probably just prior to emplacemen

Seismic and geochemical evidence for large-scale mantle upwelling beneath the eastern Atlantic and western and central Europe

Seismic tomography and the isotope geochemistry of Cenozoic volcanic rocks suggest the existence of a large, sheet-like region of upwelling in the upper mantle which extends from the eastern Atlantic Ocean to central Europe and the western Mediterranean. A belt of extension and rifting in the latter two areas appears to lie above the intersection of the centre of the upwelling region with the base of the lithosphere. Lead, strontium and neodymium isotope data for all three regions converge on a restricted composition, inferred to be that of the upwelling mantle

Enhanced carbon pump inferred from relaxation of nutrient limitation in the glacial ocean

The modern Eastern Equatorial Pacific (EEP) Ocean is a large oceanic source of carbon to the atmosphere. Primary productivity over large areas of the EEP is limited by silicic acid and iron availability, and because of this constraint the organic carbon export to the deep ocean is unable to compensate for the outgassing of carbon dioxide that occurs through upwelling of deep waters. It has been suggested that the delivery of dust-borne iron to the glacial ocean, could have increased primary productivity and enhanced deep-sea carbon export in this region, lowering atmospheric carbon dioxide concentrations during glacial periods. Such a role for the EEP is supported by higher organic carbon burial rates documented in underlying glacial sediments but lower opal accumulation rates cast doubts on the importance of the EEP as an oceanic region for significant glacial carbon dioxide drawdown. Here we present a new silicon isotope record that suggests the paradoxical decline in opal accumulation rate in the glacial EEP results from a decrease in the silicon to carbon uptake ratio of diatoms under conditions of increased iron availability from enhanced dust input. Consequently, our study supports the idea of an invigorated biological pump in this region during the last glacial period that could have contributed to glacial carbon dioxide drawdown. Additionally, using evidence from silicon and nitrogen isotope changes, we infer that, in contrast to the modern situation, the biological productivity in this region is not constrained by the availability of iron, silicon and nitrogen during the glacial period. We hypothesize that an invigorated biological carbon dioxide pump constrained perhaps only by phosphorus limitation was a more common occurrence in low-latitude areas of the glacial ocean

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Background Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. Methods FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762. Findings Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839–1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26–6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38–2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months. Interpretation Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function. Funding UK Stroke Association and NIHR Health Technology Assessment Programme

Osmium isotopes in Baffin Island and West Greenland picrites: implications for the ¹⁸⁷Os/¹⁸⁸Os composition of the convecting mantle and the nature of high ³He/⁴He mantle

Identifying the Os isotope composition of the prevalent, largely peridotitic, convecting mantle places important constraints on the Earth's accretion, differentiation and evolution and also has implications for the interpretation of Re-depletion ages in mantle peridotites. As partial melting preferentially samples mantle components with the lowest melting temperatures, large degree melts such as picrites should most closely reflect the peridotitic components within the source. Thus, Re–Os analyses of thirty picrites from Baffin Island and West Greenland are thought to provide a good estimate of the bulk 187Os/188Os composition of their convecting mantle source, which is indistinguishable from DMM in terms of lithophile isotopes and trace elements. In addition, the high 3He/4He of these rocks allows us to comment on the possible origins of high 3He/4He mantle. Ingrowth-corrected 187Os/188Os of the picrites ranges from 0.1267 to 0.1322. The higher 187Os/188Os samples have correspondingly lower 143Nd/144Nd which can be explained by contribution (∼ 5%) from old recycled oceanic crust, including sediment. However, Baffin Island and the earliest West Greenland picrites are remarkably uniform in composition with 187Os/188Os between 0.1267 and 0.1280, and a mean and mode of 0.1272 ± 0.0007. Such Os isotope compositions are less radiogenic than estimates of primitive upper mantle but are similar to the least radiogenic mid-ocean ridge basalts (MORB) and the most common composition of ophiolite-derived platinum-group alloys and chromites. These compositions appear to represent a source dominated by peridotite. The picrites studied record the highest known 3He/4He in the silicate Earth (up to 50 Ra). For this signature to reflect isolated domains of ancient melt depletion would require significantly less radiogenic Os isotope compositions than observed (187Os/188Os: 187Os/188Os signature to the picrites, and thus Os isotopes preclude the core as a source of high 3He/4He, unless core–mantle transfer of Os and He is decoupled. It is possible to broadly account for the Os–He and Os–Nd isotope variations by mixing of depleted MORB mantle, recycled oceanic crust and high 3He/4He primitive mantle, but it is difficult to explain each individual sample composition in this way. Alternatively, as the high 3He/4He signature is found in samples with variable Os and Nd isotope compositions, it seems likely that He is decoupled from other isotopic tracers and is dominated by minor addition of a He-rich, high 3He/4He component probably of primordial nature, although the ultimate source is unclear from our data

Research needs for mining and industrial solid waste disposal

Report of a workshop held at Colorado State University, Fort Collins, Colorado, July 22 and 23, 1976.CER76-77JN13.Under the sponsorship of the National Science Foundation, through the initiative of the Embankment Dams and Slopes Committee of ASCE; NSF Grant No. ENG 76-09380